Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus carboplatin and etoposide in first-line ES-SCLC
CTR20221310Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in small cell lung cancer (SCLC), sponsored by Qilu Pharmaceutical. Started May 2022; status: completed.
02
Drugs
QL1706
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20221310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221310.